AI주식인사이트AI Stock Insight
C

압타바이오

293780KOSDAQ

52.5 / 100

Reference Date: 2026-10-23

Financial Score16.0 / 40
News Sentiment12.5 / 25
Momentum14.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 6.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

AptaBio is a specialized pharmaceutical company developing innovative drugs based on three platform technologies: oxidative stress modulation, CAF Modulation, and aptamer-drug conjugate (Apta-DC). The company focuses on drug pipeline development, including eight therapeutic candidates, and expanded into health functional food ODM and pet care businesses through its newly established New Business Division in 2023. Key revenue streams include technology fees, reagent sales, and product sales from new business segments.

Number of Employees

45people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
3.96Industry Average 1.200.0Point

3.3x industry avg (risky)

ROE
-32.25Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
6.63Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲473.9% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲0.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -34.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (41%)

Current 6,650Won52-week high 10,42052-week low 4,000
1-month return4.0Point

1m +6.74% (slight rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral투자판단관련주요경영사항(임상시험결과) (조영제유발급성신장손상(CIAKI) 치료제 Isuzinaxib(APX115)의 임상시험 제2상 Topline data수령)2026-10-14